Quest for the right Drug
טמבוקור 100 מ"ג טבליות TAMBOCOR 100 MG TABLETS (FLECAINIDE ACETATE)
תרופה במרשם
תרופה בסל
נרקוטיקה
ציטוטוקסיקה
צורת מתן:
פומי : PER OS
צורת מינון:
טבליה : TABLETS
עלון לרופא
מינוניםPosology התוויות
Indications תופעות לוואי
Adverse reactions התוויות נגד
Contraindications אינטראקציות
Interactions מינון יתר
Overdose הריון/הנקה
Pregnancy & Lactation אוכלוסיות מיוחדות
Special populations תכונות פרמקולוגיות
Pharmacological properties מידע רוקחי
Pharmaceutical particulars אזהרת שימוש
Special Warning עלון לרופא
Physicians Leaflet
Posology : מינונים
4.2 Posology and method of administration Adults: Supraventricular arrhythmias: The recommended starting dosage is 50mg twice daily and most patients will be controlled at this dose. If required the dose may be increased to a maximum of 300mg daily. Ventricular arrhythmias: The recommended starting dosage is 100mg twice daily. The maximum daily dose is 400mg and this is normally reserved for patients of large build or where rapid control of the arrhythmia is required. After 3-5 days it is recommended that the dosage be progressively adjusted to the lowest level which maintains control of the arrhythmia. It may be possible to reduce dosage during long-term treatment. Children: Tambocor tablets is not recommended in children under 12, as there is insufficient evidence of its use in this age group. Elderly Patients: The rate of flecainide elimination from plasma may be reduced in elderly people. This should be taken into consideration when making dose adjustments. Plasma levels: Based on PVC suppression, it appears that plasma levels of 200-1000 ng/ml may be needed to obtain the maximum therapeutic effect. Plasma levels above 700-1000 ng/ml are associated with increased likelihood of adverse experiences. Renal impairment: In patients with significant renal impairment (creatinine clearance of 35ml/min/1.73 sq.m. or less) the maximum initial dosage should be 100mg daily (or 50mg twice daily). When used in such patients, frequent plasma level monitoring is strongly recommended. It is recommended that intravenous treatment with Tambocor should be administered in hospitals. Treatment with oral Tambocor should be under direct hospital or specialist supervision for patients with: a) AV nodal reciprocating tachycardia; arrhythmias associated with Wolff-Parkinson- White Syndrome and similar conditions with accessory pathways b) Paroxysmal atrial fibrillation in patients with disabling symptoms. Treatment for patients with other indications should continue to be initiated in hospital. Tambocor 100 mg tablets can be divided, in order to administer 50 mg dose.
שימוש לפי פנקס קופ''ח כללית 1994
Life-threatening ventricular arrhythmias such as ventricular tachycardia. התרופה תימצא רק בבתי חולים ותנופק לחולים אמבולטורים רק באמצעותם
תאריך הכללה מקורי בסל
01/01/1995
הגבלות
תרופה אשפוזית לפי החלטת משרד הבריאות
מידע נוסף